VDJ
Haidian · Founded 2011
About VDJ
VDJ is an antibody affinity enhancement platform that simulates the maturation mechanism of human antibodies and is specialized in autoimmune diseases. Their products include IL-6R antibodies and CTLA-4-Ig. They serve markets.
Company Facts
- Founded: 2011
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $8.5M
- Funding stage: Late Stage Venture
- Last round: Series C (Jun 2023)
- Website: https://www.vdjbio.com/
- Phone: 010-62987077
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/vdj-140468 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.